These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 9449278)

  • 1. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
    Marco F; Pfaller MA; Messer S; Jones RN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
    Drago M; Scaltrito MM; Morace G;
    Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
    Swinne D; Watelle M; Van der Flaes M; Nolard N
    Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
    Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Monzón A; Rodríguez-Tudela JL
    Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):432-5. PubMed ID: 10442422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN; Diekema DJ
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1723-7. PubMed ID: 12019081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
    Swinne D; Watelle M; Nolard N
    Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
    Uzun O; Arikan S; Kocagöz S; Sancak B; Unal S
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
    Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
    Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN; Doern GV; Brandt ME; Hajjeh RA
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3242-4. PubMed ID: 9835520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, and flucytosine in Candida bloodstream isolates from 15 tertiary hospitals in Korea.
    Jung SI; Shin JH; Choi HJ; Ju MY; Kim SH; Lee WG; Park YJ; Lee K;
    Ann Lab Med; 2012 Nov; 32(6):426-8. PubMed ID: 23130342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
    González GM; Elizondo M; Ayala J
    J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.
    Pfaller MA; Messer S; Jones RN
    Antimicrob Agents Chemother; 1997 Feb; 41(2):233-5. PubMed ID: 9021172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
    Nguyen MH; Yu CY
    J Antimicrob Chemother; 1998 Aug; 42(2):253-6. PubMed ID: 9738846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method.
    Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR
    Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.